| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
URGN
Urogen Pharma
|
Aug 05, 2026 | BUY |
Strong Buy
-2.2% avg upside
16 analysts
|
$60.00
29.27% Upside
|
· | · |
|
OCUL
Ocular Therapeutix
|
Aug 03, 2026 | BUY |
Strong Buy
+189.9% avg upside
21 analysts
|
$20.00
135.21% Upside
|
· | · |
|
LNTH
Lantheus
|
Aug 03, 2026 | HOLD |
Buy
-18.7% avg upside
21 analysts
|
$102.50
1.01% Upside
|
-0.2% | · |
|
TGTX
TG Therapeutics
|
Aug 03, 2026 | BUY |
Strong Buy
-16.6% avg upside
19 analysts
|
$75.00
50.40% Upside
|
+0.1% | · |
|
BCYC
Bicycle Therapeutics
|
Jul 30, 2026 | BUY |
Strong Buy
+493.5% avg upside
21 analysts
|
— | -4.7% | · |
|
IRON
Disc Medicine
|
Jul 30, 2026 | BUY |
Strong Buy
+11.1% avg upside
21 analysts
|
— | -1.6% | · |
|
PTGX
Protagonist Therapeutics
|
Jul 20, 2026 | BUY |
Strong Buy
-28.4% avg upside
19 analysts
|
$155.00
12.82% Upside
|
+8.9% | · |
|
KLRS
Kalaris Therapeutics
|
Jun 15, 2026 | BUY |
Buy
+202.2% avg upside
13 analysts
|
— | -1.9% | · |
|
STRO
Sutro Biopharma
|
May 14, 2026 | BUY |
Strong Buy
+53.9% avg upside
20 analysts
|
— | -37.1% | · |
|
CELC
Celcuity
|
May 14, 2026 | BUY |
Strong Buy
+34.2% avg upside
16 analysts
|
— | -31.7% | · |
|
FATE
Fate Therapeutics
|
May 13, 2026 | HOLD |
Buy
+362.9% avg upside
31 analysts
|
— | +16.4% | · |
|
XNCR
Xencor
|
May 11, 2026 | BUY |
Strong Buy
+71.5% avg upside
27 analysts
|
— | +56.4% | · |
|
RCKT
Rocket Pharmaceuticals
|
May 10, 2026 | HOLD |
Buy
+370.7% avg upside
29 analysts
|
— | -4.2% | · |
|
WHWK
Whitehawk Therapeutics
|
May 07, 2026 | HOLD |
Buy
+204.9% avg upside
14 analysts
|
— | -2.3% | · |
|
MLYS
Mineralys Therapeutics, Inc.
|
May 06, 2026 | BUY |
Strong Buy
+68.1% avg upside
12 analysts
|
— | -10.4% | · |
|
PCVX
Vaxcyte
|
May 06, 2026 | BUY |
Strong Buy
+86.3% avg upside
15 analysts
|
$75.00
34.16% Upside
|
-4.2% | · |
|
EYPT
EyePoint Pharmaceuticals
|
May 06, 2026 | BUY |
Strong Buy
+177.3% avg upside
20 analysts
|
$20.00
63.19% Upside
|
-12.6% | · |
|
GERN
Geron
|
May 06, 2026 | BUY |
Strong Buy
+165.2% avg upside
19 analysts
|
$3.00
84.06% Upside
|
-15.8% | · |
|
NBTX
Nanobiotix
|
Apr 01, 2026 | BUY |
Strong Buy
-16.2% avg upside
5 analysts
|
— | +10.9% | · |
|
TCRX
TScan Therapeutics
|
Mar 11, 2026 | BUY |
Strong Buy
+1021.2% avg upside
12 analysts
|
— | -35.5% | · |
|
MGNX
MacroGenics
|
Mar 10, 2026 | HOLD |
Buy
+350.8% avg upside
25 analysts
|
— | +7.6% | · |
|
AU:TLX
Telix Pharmaceuticals
|
Feb 19, 2026 | BUY |
Strong Buy
+70.5% avg upside
14 analysts
|
$20.00
35.83% Upside
|
+34.9% | · |
|
NCNA
Nucana
|
Mar 14, 2025 | HOLD |
Buy
+840.3% avg upside
9 analysts
|
— | · | · |
|
IMA
ImageneBio
|
Aug 09, 2024 | BUY |
Buy
+192.8% avg upside
12 analysts
|
— | -24.8% | · |
|
CBIO
Crescent Biopharma
|
Jul 26, 2024 | HOLD |
Strong Buy
+41.2% avg upside
17 analysts
|
— | -44.6% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.